



Healthcare
Improvement
Scotland

SMC
Advice on new
medicines

www.scottishmedicines.org.uk

Statement of advice
SMC 2864

belzutifan film-coated tablets (Welireg®)

Merck Sharp & Dohme (UK) Limited

08 August 2025

ADVICE: in the absence of a submission from the holder of the marketing authorisation:

belzutifan (Welireg®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with a programmed death receptor-1 (PD-1) / programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium